The Brewer Group Announces Strategic Partnership with TNI BioTech, Inc. TBG and TNIB join forces to address the critical need for quality treatments to combat chronic, life-threatening diseases in developing countries around the world

MINNEAPOLIS and ORLANDO, Fla., March 7, 2014 /PRNewswire/ -- The Brewer Group, Inc. ("TBG") a global investment advisory firm, today announced a new strategic partnership with TNI BioTech, Inc. ("TNIB") (OTCQB: TNIB), a biotechnology company pioneering the development of innovative therapies for autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system. Through a variety of business development strategies including exclusive access to its extensive global reach, TBG will provide tailored services including investment banking advisory as well as government, investor relations and marketing support to TNIB in an effort to offer affordable treatment technologies to those in need for as low as $1.00 USD per day in numerous markets throughout the world.

TNIB's products, technologies and patents are designed to harness the power of the immune system to improve the treatment of cancer and infections, such as HIV/AIDS and autoimmune diseases. TBG will use their established international network and deep relationships to help accelerate and advance TNIB's growth in various international markets as well as assist with global distribution while continuing TBG's mission of "A Global Vision with a Social Focus."

The Brewer Group and TNIB are fully committed to continuing their efforts toward establishing state-of-the-art oncology clinics in regions where cancer care is currently virtually non-existent. In other areas where there is already an existing foundation, the companies will work to strengthen the pre-existing care through donations of additional medicines and offering expertise and advice. As cancer is now the leading cause of death worldwide and particularly affects developing countries, the two organizations hope to provide an innovative solution for underserved communities and individuals who cannot afford the quality care that they need.

"Partnering with TNI BioTech to bring cancer care to the people who need it most is truly a Godsend for me," said His Excellency Ambassador Jack Brewer, The Brewer Group Chief Executive Officer. "I have always strived to provide quality medical aid and relief, and this will be a unique opportunity for our firm to provide innovative, affordable technologies and create a sustainable oncology treatment system in countries where there is currently little or no care."

The partnership will specifically focus on global expansion using TBG's exclusive network and established relationships with key international decision makers spanning government development agencies, financial institutions, private equity firms, corporations, NGO's and major distribution partners in numerous continents including throughout the Caribbean, Latin America and in various regions of Africa.

Noreen Griffin, Chief Executive Officer of TNI BioTech, said, "We have spent the last year forming top-level relationships with some of the most influential companies and people in Africa, Latin America and the Caribbean.  We have manufactured more than one million pills anticipating sales to Nigeria this quarter and we are building an international sales network through recognized distributors.  We are excited to build upon the work we have already started with His Excellency Ambassador Jack Brewer and his team at The Brewer Group."

About The Brewer Group, Inc.

The Brewer Group, Inc. ("TBG") is a diversified global investment advisory firm focused on providing tailored services to its clients spanning numerous sectors including: Biotechnology; Sustainable Technology & Agriculture; Wearable Technology & Consumer Products; Hospitality; Education & Cultural Exchange; and Sports, Media & Entertainment. TBG relationships with key international decision makers spanning government development agencies, financial institutions, private equity firms, corporations, NGO's and numerous leaders in sports and entertainment place the firm in a unique position to execute a wide range of services. For further information, please visit www.thebrewergroup.com or follow them on Twitter.

About TNI BioTech, Inc.

TNI BioTech, Inc. ("TNIB") is a biotech company working to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system using our patented immunotherapy. TNIB's products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.

TNI BioTech's proprietary technology, therapies and patents include the treatment of a wide range of cancers. The Company's most advanced clinical programs involve immunotherapy with met-enkephalin ("MENK") (sometimes referred to as opioid growth factor ("OGF")) and Low Dose Naltrexone product ("LDN"), which have been shown to stimulate the immune system even in patients with advanced cancer. Even though management considers any condition that results in altered-immune response a target for investigation, the Company will most likely pursue additional investigations for MENK and LDN as valuable candidates in the treatment of the following: autoimmune states such as rheumatoid arthritis and multiple sclerosis; as an adjunct in cancer patients undergoing chemotherapy, radiation treatments or surgery; and as an adjunct to antibiotics in the treatment of a variety of infectious diseases, including patients with AIDS, in combination with retroviral drug therapy. For further information, please see http://www.tnibiotech.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release and the statements of representatives and partners of TNI Biotech, Inc. and its subsidiaries (the "Company") related thereto include various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the Company's expectations or beliefs concerning future events. Statements containing expressions such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" used in the Company's press releases and in the Company's filings with the Securities and Exchange Commission as well as Disclosure Statements and Reports filed with the Over The Counter Markets through the OTC Disclosure and News Service are intended to identify forward-looking statements. All forward-looking statements involve assumptions and significant risks and uncertainties. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release, and thus readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date thereof. Actual results (including, without limitation, the Company's actual sales results for 2014 and the impact of the Certificate of Free Sale described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly release any revisions to such forward-looking statements to reflect events or circumstances after the date hereof.

The Brewer Group Contact:
Kristi Hofacker, Interactive Marketing and Media Manager
651-247-4460
Kristi.Hofacker@thebrewergroup.com 

TNI BioTech Contact:
Dennis S. Dobson
203-258-0159
dennisdobsonjr@dobsonmediagroup.com

SOURCE TNI BioTech, Inc.



RELATED LINKS
http://www.tnibiotech.com
http://www.thebrewergroup.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.